

HRSA Criteria For Authorization of Suboxone® (buprenorphine/naloxone)

Before authorization will be approved, the patient must meet all of the following criteria.

The patient:

1. Is 16 years of age or older;
2. Has a DSM-IV-TR diagnosis of opioid dependence;
3. Is psychiatrically stable or is under the supervision of a mental health specialist;
4. Is not abusing alcohol, benzodiazepines, barbiturates, or other sedative-hypnotics;
5. Is not pregnant or nursing;
6. Does not have a history of failing multiple previous opioid agonists treatments and multiple relapses;
7. Does not have concomitant prescriptions of azole antifungal agents, macrolide antibiotics, protease inhibitors, phenobarbital, carbamazepine, phenytoin, and rifampin, unless dosage adjusted appropriately; and
8. Is enrolled in a state-certified intensive outpatient chemical dependency treatment program. See WAC 388-805-610.

Limitations:

- No more than 14-day supply may be prescribed at a time;
- Urine drug screens for benzodiazepines, amphetamine/ methamphetamine, cocaine, methadone, opiates, and barbiturates must be done before each prescription is dispensed. The prescriber must ensure that the drug screen has been completed prior to prescribing the next 14-day supply.
- Liver function tests must be monitored periodically to guard against buprenorphine-induced hepatic abnormalities; and
- Clients may receive up to 6 months of buprenorphine treatment for detoxification and stabilization.

A Buprenorphine-Suboxone Authorization Form (DSHS 13-720) must be completed and sent to DASA before authorization is issued. **To download a copy, go to:**
<http://www1.dshs.wa.gov/msa/forms/eforms.html>.